Hiatal hernia and the risk of Barrett's esophagus

Andrici, Juliana; Tio, Martin; Cox, Michael R.; Eslick, Guy D.

doi:10.1111/j.1440-1746.2012.07199.x

Cited by 66 publications

(32 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The discovery phase used age-matched serum samples from 9 healthy, 10 BE, and 10 EAC male patients (Table I). BE and EAC patient groups had a significantly higher proportions of patients with hiatus hernia compared with healthy controls, as has previously been reported (48). We identified a total of 195 unique proteins from the MS/MS data (supplemental Table S2).…”

Section: Resultssupporting

confidence: 56%

Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma

Shah

Cao

Choi

et al. 2015

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

We report an integrated pipeline for efficient serum glycoprotein biomarker candidate discovery and qualification that may be used to facilitate cancer diagnosis and management. The discovery phase used semi-automated lectin magnetic bead array (LeMBA)-coupled tandem mass spectrometry with a dedicated data-housing and analysis pipeline; GlycoSelector (http://glycoselector.di. uq.edu.au). The qualification phase used lectin magnetic bead array-multiple reaction monitoring-mass spectrometry incorporating an interactive web-interface, Shiny mixOmics (http://mixomics-projects.di.uq.edu.au/Shiny), for univariate and multivariate statistical analysis. Relative quantitation was performed by referencing to a spiked-in glycoprotein, chicken ovalbumin. We applied this workflow to identify diagnostic biomarkers for esophageal adenocarcinoma (EAC), a life threatening malignancy with poor prognosis in the advanced setting. EAC develops from metaplastic condition Barrett's esophagus (BE). Currently diagnosis and monitoring of at-risk patients is through endoscopy and biopsy, which is expensive and requires hospital admission. Hence there is a clinical need for a noninvasive diagnostic biomarker of EAC. In total 89 patient samples from healthy controls, and patients with BE or EAC were screened in discovery and qualification stages. Of the 246 glycoforms measured in the qualification stage, 40 glycoforms (as measured by lectin affinity) qualified as candidate serum markers. The top candidate for distinguishing healthy from BE patients' group was Narcissus pseudonarcissus lectin (

show abstract

Section: Resultssupporting

confidence: 56%

Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma

Shah

Cao

Choi

et al. 2015

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

show abstract

“…All samples were age matched and collected from male patients. BE and EAC patient groups had significantly higher proportion of patients with hiatus hernia compared to the healthy group, as has previously been reported (383), suggesting hiatus hernia to be a risk factor for BE/EAC. A total of 195 unique proteins were identified from the LeMBA-MS/MS screen.…”

Section: Be/eac Biomarker Discoverysupporting

confidence: 70%

Serum diagnostic glycoprotein biomarkers for Barrett's esophagus and esophageal adenocarcinoma

Shah¹

View full text Add to dashboard Cite

Esophageal cancer is the eighth most commonly diagnosed cancer and the sixth most common cause of cancer related mortality globally. There are two different types of esophageal cancer, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), each accounting for half of the cases. EAC develops in the lower one third of the esophagus as a consequence of chronic gastroesophageal reflux disease (GERD) from precancerous metaplastic condition Barrett's esophagus (BE). Apart from GERD and BE which are major risk factors for EAC, other known risk factors include age, male gender, obesity, Caucasian race, low intake of fruits and vegetables in diet, and Helicobacter pylori negative status. Due to changing life style and prevalence of risk factors, the incidences of EAC have been rising for past few decades and now it has become one of the fastest growing malignancies. The survival rate is very poor with only 1 in 5 patients survive more than 5 years after EAC diagnosis, likely due to diagnosis at late stages. To diagnose early treatable dysplastic changes in progression from BE to EAC, BE patients undergo routine endoscopy-biopsies, with the biopsy evaluated by a histopathologist to confirm the dysplastic changes. This current method is invasive and prone to sampling error as well as interobserver variability. Endoscopy requires patient hospitalization and specialist appointment, leading to high expense. Moreover, BE is an asymptomatic condition which means a pool of BE patients are undiagnosed hence not enrolled into the surveillance program. Collectively, it has been shown that current endoscopy-biopsies based diagnostic is impractical and expensive for population wide BE screening or surveillance programs.In contrast to endoscopy-biopsy, biomarkers from the blood are amenable to populationscreening strategies, due to the ease of access and low cost of testing. Moreover, EAC pathogenesis has been associated with changes in the serum glycan profile. However, specific glycoproteins that undergo differential glycosylation are unknown. Therefore, the aims of this thesis were to (i) identify serum diagnostic glycoprotein biomarker candidates for BE and EAC using biomarker discovery pipeline, (ii) develop a targeted proteomics approach to measure biomarker candidates for timely verification, (iii) verify serum glycoprotein candidates in an independent patient cohort, and (iv) test feasibility of using electrochemical detection methodology for the glycoprotein detection.This translational research project utilizes lectins, naturally occurring proteins with specificity to bind with glycan structures, as affinity agents to isolate glycoproteins with different glycan structures. Our laboratory has previously established lectin magnetic bead array (LeMBA) methodology to identify serum glycoprotein biomarker candidates showing differential lectin ii binding (Loo et al., J Proteome Res 2010 and Choi et al., Electrophoresis 2011 Mass spectrometry methods employed for biomarker discovery and verification...

show abstract

“…9 Here, hiatal hernia length was strongly correlated to BO length (see Figure 1) which augments a recent meta-analysis on this topic. 10 We also observed large weight gains from young adulthood may cause an earlier onset of BO, but they do not correlate with BO length. …”

Section: Acknowledgementmentioning

confidence: 49%

Letter: future directions for epidemiological studies of Barrett's oesophagus

Nathanson

Navab

2015

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Hiatal hernia and the risk of Barrett's esophagus

Abstract: The presence of hiatal hernia was associated with an increased risk of Barrett's esophagus, even after adjusting for clinically significant confounders. The strongest association was found between hiatal hernia and long segment Barrett's esophagus.

Cited by 66 publications

References 74 publications

Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma

Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma

Serum diagnostic glycoprotein biomarkers for Barrett's esophagus and esophageal adenocarcinoma

Letter: future directions for epidemiological studies of Barrett's oesophagus

Contact Info

Product

Resources

About